
CERTARA INC
CERTNASDAQTrading Snapshot
- Day Range
- $7.90 โ $8.12
- 52-Week Range
- $4.45 โ $13.88
- Volume
- $2.00B
- Avg Volume
- $2.24B
- Shares Outstanding
- 155.6M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $419M
- Last Q Revenue
- $93M
- P/E Ratio
- -18.3
- P/S Ratio
- 3.1x
- EPS (TTM)
- $-0.44
- Dividend Yield
- 0.00%
Why Investors Own CERT
- โHigh-growth profile โ revenue up +29.7% YoY with expanding US Equity exposure.
- โHealthy economics โ 79% gross margin and 22% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About CERTARA INC
Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

The Bull Case For Certara (CERT) Could Change Following Wider Q2 Loss And Leadership Shake-Up - Learn Why
In early August 2026, Certara reported second-quarter results showing slightly higher sales of US$93.27 million but a much larger net loss of US$55.27 million, alongside executive reshuffling including the departure of President and Chief Commercial Officer Leif Pedersen and the appointment of Julien Perrier as Chief Commercial Officer and Eric Jahn as Chief Information Officer. At the same time, Certara reaffirmed its 2026 revenue outlook while expanding its share repurchase authorization...
Barclays Maintains Equal-Weight on Certara, Raises Price Target to $7.5
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Equal-Weight and raises the price target from $6.5 to $7.5.

Certara (CERT) Q2 2026 Earnings Call Transcript
Software revenue hit 53% of total as AI-assisted code boosted development 65% year over year.

Certara, Inc. Q2 2026 Earnings Call Summary
Moby summary of Certara, Inc.'s Q2 2026 earnings call

Certara, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-04. The following slide deck was published by Certara, Inc.

Certara, Inc. (CERT) Q2 2026 Earnings Call Transcript
Certara, Inc. (CERT) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDTCompany ParticipantsJon Resnick - CEO & DirectorFaiz Mohammed - Interim CFO, Senior...